Article Describing AXONYX's Novel Alzheimer's Disease Treatment Chosen as a ``Hot Article'' by the American Chemical Society.NEW YORK--(BW HealthWire)--Nov. 4, 1999-- AXONYX Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AXYX) announced today that the American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in (ACS (Asynchronous Communications Server) See network access server. ) has chosen an article covering the synthesis of AXONYX's new class of experimental therapeutics which have potential application in the treatment of Alzheimer's Disease (AD) as one of two "hot articles" for 1999. This article authored by Nigel H. Greig et. al., entitled "Synthesis of Novel Phenserine-Based-Selective Inhibitors of Butyrylcholinesterase for Alzheimer's Disease" (see AXONYX Press Release- May 19, 1999) was published in the May 20, 1999 edition of the Journal of Medicinal Chemistry The Journal of Medicinal Chemistry (usually abbreviated as J. Med. Chem.), is a peer-reviewed scientific journal, published since 1959 by the American Chemical Society. and describes a unique approach to treating AD. "Researchers have developed an array of new chemicals that may attack Alzheimer's Disease in a unique way. The compounds target a little understood enzyme called butyrylcholinesterase, which has recently been shown to be elevated in the brains of patients with AD," stated the Journal of Medicinal Chemistry. Marvin S. Hausman, M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of AXONYX, congratulates Dr. Nigel Greig, Chief, Drug Design and Development within the Intramural intramural /in·tra·mu·ral/ (-mu´r'l) within the wall of an organ. in·tra·mu·ral adj. Occurring or situated within the walls of a cavity or organ. Research Program at the National Institute on Aging The National Institute on Aging is a division of the U.S. National Institutes of Health, located in Bethesda, Maryland. Formed in 1974, NIA's mission is to improve the health and well-being of older Americans through research. It is the primary U.S. , National Institutes of Health for his work on the synthesis and development of these unique compounds. He continues to say, "This novel platform technology offers AXONYX a number of promising opportunities to develop unique compounds for the treatment of Alzheimer's Disease." AXONYX Inc. is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease and other memory disorders. This press release may contain forward-looking statements or predictions. These statements represent our judgement as of this date and are subject to risks and uncertainties that could materially affect the Company. AXONYX undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events of circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion